By Sheeba M. | June 2, 2026
Section 280E Repeal Could Add $800M in Annual Sector EBITDA—Congress Signals Momentum
Federal cannabis policy moves in inches, not miles. But sometimes those inches compound. The conversation around Section 280E repeal—the 1982 tax code provision that prevents cannabis companies from deducting cost of goods sold—has shifted from hypothetical to legislative reality.
What Is Section 280E?
In plain English: Cannabis companies pay corporate income tax on gross revenue, not net profit. A typical MSO with $500M in revenue and $100M in COGS pays federal tax on the full $500M as if it were profit. For comparison, a pharma or consumer goods company would only pay tax on net income after COGS deduction.
The impact is brutal. Effective tax rates for MSOs hit 40-50% before state taxes, versus 15-25% for comparable legal industries. It’s a hidden levy on the entire sector.
The Legislative Path Forward
The “Cannabis Reinvestment Initiative” bill (HR 7277, introduced March 2026) has gained surprising bipartisan traction. Current co-sponsors include:
- Agriculture Committee members (Colorado, California, Oregon districts)
- Appropriations Subcommittee on Interior (cannabis-friendly states)
- Tax policy hawks from both parties
The bill pairs 280E repeal with:
- Federal banking access (SAFE repackaged)
- $200M research funding for agricultural efficiency
- Phase-in over 3 years to prevent revenue shock
Political betting markets give it a 35-45% chance of reaching a vote in 2026-2027. Not a sure thing, but the first time it’s been genuinely viable.
The Math for Curaleaf, Trulieve, and Cresco
Model conservatively: 280E repeal creates an effective 10-12 percentage point tax rate reduction (phased in). For the “Big 4” MSOs, that translates to:
- Curaleaf: $180-220M annual tax savings (Phase 3)
- Trulieve: $140-180M annual tax savings
- Greenthumb: $120-150M annual tax savings
- Verano: $80-110M annual tax savings
That’s roughly $500-800M in aggregate EBITDA relief, depending on phase-in speed. Capitalized at 10-12x multiples (typical for the sector), that’s $5-9.6B in shareholder value creation.
Why Now?
Two forces: (1) Cannabis tax revenue for states has stabilized and predictable—Congress is less worried about cannibalizing state programs. (2) MSOs are now demonstrating consistent profitability at the operating level, making them less “risky” for tax relief. Lawmakers feel safer saying “these are real businesses.”
Don’t count on it this year. But watch voting behavior in July when HR 7277 committee mark-up occurs. If the bill advances, expect MSO valuations to expand 15-20% on the headline alone.
Sources
- Congress.gov — HR 7277 status and co-sponsor tracking
- Bloomberg Tax — Section 280E impact analysis
- SEC EDGAR — MSO effective tax rate disclosures in 10-K filings
Track cannabis stocks with the Weedstock Real-Time Tracker